REDUCTION OF N-HYDROXYLATED COMPOUNDS: AMIDOXIMES (N-HYDROXYAMIDINES) AS PRO-DRUGS OF AMIDINES

REFERENCES

• Testa B. Biochemistry of Redox Reactions. The Metabolism of Drugs and Other Xenobiotics, B. Testa, J. Caldwell. Academic Press, London 1995; 398–447
   Google Scholar
• Clement B. Oxidation and Reduction of Nitrogen via CYP450: Importance of the Reduction of Genotoxic N-Hydroxylated Functional Groups. Drug Metabolism: Towards the Next Millennium. IOS Press, Amsterdam 1998; 59–71
   Google Scholar
• Clement B. The N-Oxidation of Benzamidines In Vitro. Xenobiotica 1983; 13: 467–473
   PubMed Web of Science ®Google Scholar
• Clement B., Zimmermann M. Mechanism of the Microsomal N-Hydroxylation of Parasubstituted Benzamidines. Biochem. Pharmacol. 1988; 37: 4747–4752
   PubMed Web of Science ®Google Scholar
• Clement B., Jung F., Pfundner H. N-Hydroxylation of Benzamidine to Benzamidoxime by a Reconstituted Cytochrome P450 Oxidase System from Rabbit Liver: Involvement of P450 IIC3. Mol. Pharmacol. 1993; 43: 335–342
   PubMed Web of Science ®Google Scholar
• Clement B., Jung F. N-Hydroxylation and N-Dealkylation by P450 2C3 of N-Methylbenzamidine: N-Oxygenation and N-Oxidative Dealkylation of One Functional Group. Xenobiotica 1995; 25: 443–455
   PubMed Web of Science ®Google Scholar
• Clement B., Jung F. N-Hydroxylation of the Antiprotozoal Drug Pentamidine Catalyzed by Rabbit Liver Cytochrome P450 2C3 or by Human Liver Microsomes, Microsomal Retroreduction and Further Oxidative Transformation of the Formed Amidoximes, Possible Relationship to the Biological Oxidation of Arginine to NG-Hydroxyarginine, Citrulline and Nitric Oxide. Drug Metab. Dispos. 1994; 22: 486–497
   PubMed Web of Science ®Google Scholar
• Clement B., Kunze T. The In Vitro Oxygenation of N,N′-Diphenylguanidines. Xenobiotica 1993; 23: 155–167
   PubMed Web of Science ®Google Scholar
• Clement B., Schultze-Mosgau M.H., Wohlers H. Cytochrome P450 Dependent N-Hydroxylation of a Guanidine (Debrisoquine), Microsomal Catalyzed Reduction and Further Oxidation of the N-Hydroxyguanidine Metabolite to the Urea Derivative: Similarly with the Oxidation of Arginine to Citrulline and NO. Biochem. Pharmacol. 1993; 46: 2249–2267
   PubMed Web of Science ®Google Scholar
• Clement B., Schultze-Mosgau M.H., Richter P.H., Besch A. Cytochrome P450 Dependent N-Hydroxylation of an Aminoguanidine (Amidinohydrazone) and Microsomal Retroreduction of the N-Hydroxylated Product. Xenobiotica 1994; 24: 671–688
   PubMed Web of Science ®Google Scholar
• Clement B., Demesmaeker M., Linne S. Microsomal Catalyzed N-Hydroxylation of Guanabenz and Reduction of the N-Hydroxylated Metabolite: Characterization of the Two Reactions and Genotoxic Potential of Guanoxabenz. Chem. Res. Toxicol. 1996; 9: 682–688
   PubMed Web of Science ®Google Scholar
• Clement B., Demesmaeker M. Formation of Guanoxabenz from Guanabenz in Human Liver: A New Metabolic Marker for CYP1A2. Drug Metab. Dispos. 1997; 25: 1266–1271
   PubMed Web of Science ®Google Scholar
• Clement B., Schmitt S., Zimmermann M. Enzymatic Reduction of Benzamidoxime to Benzamidine. Arch. Pharm. 1988; 321: 955–956
   PubMed Web of Science ®Google Scholar
• Hautpmann J., Paintz M., Kaiser B., Richter M. Reduction of a Benzamidoxime Derivate to the Corresponding Benzamidine In Vivo and In Vitro. Pharmazie 1988; 43: 559–560
   PubMed Web of Science ®Google Scholar
• Clement B., Zimmermann M., Schmitt S. Biotransformation des Benzamidins und des Benzamidoxims Durch Mikrosomale Enzyme von Kaninchen. Arch. Pharm. 1989; 322: 431–436
   PubMedGoogle Scholar
• Clement B., Immel M., Schmitt S., Steinmann U. Biotransformations of Benzamidine and Benzamidoxime In Vivo. Arch. Pharm. 1993; 326: 807–812
   PubMed Web of Science ®Google Scholar
• Clement B., Lomb R., Möller W. Isolation and Characterization of the Protein Components of the Liver Microsomal O2 Insensitive NADH–Benzamidoxime Reductase. J. Biol. Chem. 1997; 272: 19615–19620
   PubMed Web of Science ®Google Scholar
• Blume H., Oelschläger H. Über den Arzneistoffmetabolismus Durch Mitochondrien aus Rattenleber. Arzneim. Forsch./Drug Res. 1978; 28: 956–960
   PubMedGoogle Scholar
• Kline E.S., Brandt R.B., Laux J.E., Spainhour S.E., Higgins E.S., Rogers K.S., Tinsley S.B., Waters M.G. Localization of l-Lactate Dehydrogenase in Mitochondria. Arch. Biochem. Biophys. 1986; 246: 673–680
   PubMed Web of Science ®Google Scholar
• Sottocasa G., Kuylenstierna B., Ernster L., Bergstrand A. An Electron-Transport System Associated with the Outer Membrane of Liver Mitochondria. J. Cell Biol. 1967; 32: 415–438
   PubMed Web of Science ®Google Scholar
• Takesue S., Omura T. Immunological Similarity Between NADH–Cytochrome c Reductases of Mitochondrial Outer Membrane and Microsomes. Biochem. Biophys. Res. Commun. 1970; 40: 396–401
   PubMed Web of Science ®Google Scholar
• Yasukochi Y., Masters B.S.S. Some Properties of a Detergent-Solubilized NADPH–Cytochrome c (Cytochrome P450) Reductase Purified by Biospecific Affinity Chromatography. J. Biol. Chem. 1976; 251: 5337–5344
   PubMed Web of Science ®Google Scholar
• Kadlubar F.F., Ziegler D.M. Properties of a NADH-Dependent N-Hydroxy Amine Reductase Isolated from Pig Liver Microsomes. Arch. Biochem. Biophys. 1974; 162: 83–92
   PubMed Web of Science ®Google Scholar
• Postlind H., Axen E., Bergman T., Wikvall K. Clonings Structure, and Expression of a cDNA Encoding Vitamin D325-Hydroxylase. Biochem. Biophys. Res. Commun. 1997; 241: 491–497
   PubMed Web of Science ®Google Scholar
• Karhan W., Lopian K., Behrens D., Rieckert W., Clement B. Reduction of N-Hydroxylated Compounds by Human Cytochrome P4502A6, Cytochrome b5 and NADH Cytochrome b5 Reductase. Eur. J. Pharm. Sci. 2000; 11(S1)93
   Google Scholar
• Bernheim M. The Hydroxylamine Reductase of Mitochondria. Arch. Biochem. Biophys. 1969; 134: 408–413
   PubMed Web of Science ®Google Scholar
• Guengerich F.P. Common and Uncommon Cytochrome P450 Reactions Related to Metabolism and Chemical Toxicity. Chem. Res. Toxicol. 2001; 14: 612–651
   Google Scholar
• Yamazaki H., Nakano M., Imai Y., Ueng Y.-F., Guengerich F.P., Shimada T. Roles of Cytochrome b5 in the Oxidation of Testosterone and Nifedipine by Recombinant Cytochrome P450 3A4 and by Human Liver Microsomes. Arch. Biochem. Biophys. 1996; 325: 174–182
   PubMed Web of Science ®Google Scholar
• West S.B., Levin W., Ryan D., Vore M., Lu A.Y.H. Liver Microsomal Electron Transport System. II. The Involvement of Cytochrome b5 in the NADH-Dependent Hydroxylation of 3,4-Benzpyrene by a Reconstituted Cytochrome-P448-Containing System. Biochem. Biophys. Res. Commun. 1974; 58: 516–522
   PubMed Web of Science ®Google Scholar
• Walker F.A., Emrick D., Rivera J.E., Hanquet B.J., Buttlaire D.H. Effect of Heme Orientation on the Reduction Potential of Cytochrome b5. J. Am. Chem. Soc. 1988; 110: 6234–6240
   PubMed Web of Science ®Google Scholar
• Rivera M., Seetharaman R., Girdhar D., Wirtz M., Zhang X.J., Whang X.Q., White S. The Reduction Potential of Cytochrome b5 Is Modulated by Its Exposed Heme Edge. Biochemistry 1998; 37: 1485–1494
   PubMed Web of Science ®Google Scholar
• Trepanier L.A., Miller J.L. NADH-Dependent Reduction of Sulphamethoxazole Hydroxylamine in Dog and Human Liver Microsomes. Xenobiotica 2000; 30: 1111–1121
   PubMed Web of Science ®Google Scholar
• Yamada H., Baba T., Ogur K., Yoshimura H. Enzymatic Reduction of N-Hydroxyamphetamine: The Role of Electron Transfer System Containing Cytochrome b5. Biochem. Pharmacol. 1988; 37: 368–370
   PubMed Web of Science ®Google Scholar
• Clement B., Behrens D., Möller W., Cashman J.R. Reduction of Amphetamine Hydroxylamine and Other Aliphatic Hydroxylamines by Benzamidoxime-Reductase and Human Liver Microsomes. Chem. Res. Toxicol. 2000; 13: 1037–1045
   PubMed Web of Science ®Google Scholar
• Cribb A.E., Spielberg S.P., Griffin G.P. N4-Hydroxylation of Sulfamethoxazole by Cytochrome P450 of the Cytochrome P4502C Subfamiliy and Reduction of Sulfamethoxazole Hydroxylamine in Human and Rat Hepatic Microsomes. Drug Metab. Dispos. 1994; 23: 406–414
   Web of Science ®Google Scholar
• King R.S., Teitel C.H., Shaddock J.G., Casciano P.A., Kadlubar F.F. Detoxification of Carcinogenic Aromatic and Heterocyclic Amines by Enzymatic Reduction of the N-Hydroxy Derivative. Cancer Lett. 1999; 143: 167–171
   PubMed Web of Science ®Google Scholar
• Clement B., Behrens D., Möller W. Reduction of Hydroxylamines by NADH–Benzamidoxime Reductase. Arch. Pharm. 1998; 331(S2)38
   Google Scholar
• Mansuy D., Boucher J.L., Clement B. On the Mechanism of Nitric Oxide Formation upon Oxidative Cleavage of C= N(OH) Bonds by NO-Synthases and Cytochromes P450. Biochemie 1995; 77: 661–667
   PubMed Web of Science ®Google Scholar
• Clement B., Christiansen K., Girreser U. Phase 2 Metabolites of N-Hydroxylated Amidines (Amidoximes): Synthesis, In Vitro Formation by Pig Hepatocytes, and Mutagenicity Testing. Chem. Res. Toxicol. 2001; 14: 319–326
   PubMed Web of Science ®Google Scholar
• Van der Waterbeemd H., Smith D.A., Beaumont K., Walker D.K. Probertybased Design: Optimization of Drug Absorption and Pharmacokinetics. J. Med. Chem. 2001; 44: 1313–1333
   PubMed Web of Science ®Google Scholar
• Prentis R.A., Lis Y., Walker S.R. Pharmaceutical Innovation by the Seven UK-Owned Pharmaceutical Companies (1965–1985). Br. J. Clin. Pharmacol. 1988; 25: 387–396
   PubMed Web of Science ®Google Scholar
• Kennedy T. Managing the Drug Discovery/Development Interface. Drug Discov. Today 1997; 2: 436–444
   Web of Science ®Google Scholar
• Venkatesh S., Lipper R.A. Role of the Development Scientist in Compound Lead Selection and Optimization. J. Pharm. Sci. 2000; 89: 145–154
   PubMed Web of Science ®Google Scholar
• Clement, B. German Patents P 4321444.4, 1993 and PCT/DE 94/000756, 1994; US Patent 5,786,383, June 28, 1998; European Patent 0708640, September 16, 1998.
   Google Scholar
• Boykin D.W., Kumar A., Hall J.E., Bender B.C., Tidwell R.R. Anti-pneumocystis Activity of bis-Amidoximes and bis-o-Alkylamidoximes Prodrugs. Bioorg. Med. Chem. Lett. 1996; 6: 3017–3020
   Web of Science ®Google Scholar
• Hall J.E., Kerrigan J.E., Ramachadran K., Bender B.C., Stanko J.P., Jones S.K., Patrick D.A., Tidwell R.R. Anti-pneumocystis Activities of Aromatic Diamidoxime Prodrugs. Antimicrob. Agents Chemother. 1998; 42: 666–674
   PubMed Web of Science ®Google Scholar
• Wang S., Hall J.E., Tanious F.A., Wilson W.D., Patrick D.A., McCurdy D.R., Bender B.C., Tidwell R.R. Dicationic Dibenzofuran Derivatives as Anti-Pneumocystis carinii Pneumonia Agents: Synthesis, DNA Binding Affinity, and Anti-P. carinii Activity in an Immunosuppressed Rat Model. Eur. J. Med. Chem. 1999; 34: 215–224
   Web of Science ®Google Scholar
• Patrick D.A., Hall J.E., Bender B.C., McCurdy D.R., Wilson W.D., Tanious F.A., Saha S., Tidwell R.R. Synthesis and Anti-Pneumocystis carinii Pneumonia Activity of Novel Dicationic Dibenzothiophenes and Orally Active Prodrugs. Eur. J. Med. Chem. 1999; 34: 575–583
   PubMed Web of Science ®Google Scholar
• Weller T., Alig L., Beresini M., Blackburn B., Bunting S., Hadvary P., Hürzeler Müller M., Knoop D., Levet-Trafit J.B., Lipari M.T., Modi N.B., Müller M., Refino C.J., Schmitt M., Schönholzer P., Weiss S., Steiner B. Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. J. Med. Chem. 1996; 39: 3139–3147
   PubMed Web of Science ®Google Scholar
• Refino C.J., Modi N.B., Bullens S., Pater C., Lipari M.T., Robarge K., Blackburn B., Beresi M., Weller T., Steiner B., Bunting S. Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist Following Multiple Oral Administrations of a Prodrug Form. Thromb. Haemostasis 1998; 79: 169–176
   PubMed Web of Science ®Google Scholar
• Cannon C.P., McCabe C.H., Borzak S., Henry T.D., Tischler M.D., Mueller H.S., Feldman R., Palmeri S.T., Ault K., Hamilton S.A., Rothman J.M., Novotny W.F., Braunwald E. Randomized Trial of an Oral Platelet Glycoprotein IIb/IIIa Antagonist, Sibrafiban, in Patients After an Acute Coronary Syndrome. Circulation 1998; 97: 340–349
   PubMed Web of Science ®Google Scholar
• Wittke B., Mackie I.J., Machin S.J., Timm U., Zell M., Goggin T. Pharmacokinetics and Pharmacodynamics of Ro 44-3888 After Single Ascending Oral Doses of Sibrafiban, an Oral Platelet Aggregation Inhibitor, in Healthy Male Volunteers. Br. J. Clin. Pharmacol. 1999; 47: 521–530
   PubMed Web of Science ®Google Scholar
• Eriksson U.G., Johannson L., Frison L., Bredberg U., Gustafsson D. (Intr. by J. Hirsch) Single and Repeated Oral Dosing of H376/95, a Prodrug of the Direct Thrombin Inhibitor Melagatran, to Young Healthy Male Subjects. Blood 1999; 94(10 Suppl. 1)26a
   Web of Science ®Google Scholar
• Gustafsson D., Nyström J.-E., Carlsson S., Bredberg U., Eriksson U., Gyzander E., Elg M., Antonsson T., Hoffmann K.-J., Ungell A.-L., Sörensen H., Negard S., Abrahamsson A., Bylund R. The Direct Thrombin Inhibitor Melagatran and Its Oral Prodrug H376/95: Intestinal Absorption Properties, Biochemical and Pharmacodynamic Effects. Thromb. Res. 2001; 101: 171–181
   PubMed Web of Science ®Google Scholar